BR0111458A - Métodos de tratamento ou profilaxia de condição inflamatória, de imunoproteção e de imunopotencialização de um indivìduo, composição, computador e produto de programa de computador - Google Patents
Métodos de tratamento ou profilaxia de condição inflamatória, de imunoproteção e de imunopotencialização de um indivìduo, composição, computador e produto de programa de computadorInfo
- Publication number
- BR0111458A BR0111458A BR0111458-1A BR0111458A BR0111458A BR 0111458 A BR0111458 A BR 0111458A BR 0111458 A BR0111458 A BR 0111458A BR 0111458 A BR0111458 A BR 0111458A
- Authority
- BR
- Brazil
- Prior art keywords
- chemical
- treatment
- inflammatory condition
- prophylaxis
- computer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
"MéTODOS DE TRATAMENTO OU PROFILAXIA DE CONDIçãO INFLAMATóRIA, DE IMUNOPROTEçãO E DE IMUNOPOTENCIALIZAçãO DE UM INDIVìDUO, COMPOSIçãO, COMPUTADOR E PRODUTO DE PROGRAMA DE COMPUTADOR". A presente invenção refere-se, de forma geral, a agentes químicos úteis no tratamento e na profilaxia de condições inflamatórias ou na melhoria de sintomas resultantes ou facilitados por condição inflamatória nos mamíferos, inclusive humanos e primatas, animais não mamíferos e espécies de aves. Mais especificamente, a presente invenção proporciona um agente químico da família dos diterpenos macrocíclicos, cuja obtenção é possível a partir de um membro da família de plantas Euforbiáceas ou de seus derivados botânicos ou de horticultura ou de derivados ou análogos químicos ou formas quimicamente sintéticas dos agentes usados no tratamento ou na profilaxia de condição inflamatória ou na melhoria de sintomas resultantes ou facilitados por condição inflamatória nos mamíferos, animais e aves. A presente invenção também contempla um método para profilaxia ou tratamento de indivíduos mamíferos, animais e aves que exibem condições inflamatórias que incluem condições inflamatórias crónicas ou transitórias ou para melhoria dos sintomas de uma condição inflamatória pela administração tópica ou sistêmica de diterpenos macrocíclicos, passíveis de serem obtidos a partir de um membro da família de plantas Euforbiáceas ou de seus derivados botânicos ou de horticultura ou de um derivado, análogo químico ou forma quimicamente sintética do agente. O agente químico da presente invenção pode estar na forma de um composto purificado, de uma mistura de compostos, de uma forma precursora de um ou mais dos compostos capazes de causar transformação química num agente terapeuticamente ativo ou estar na forma de uma fração química, subtração, preparação ou extrato da planta.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPQ8017A AUPQ801700A0 (en) | 2000-06-07 | 2000-06-07 | Enzyme and viral activation |
PCT/AU2001/000680 WO2001093885A1 (en) | 2000-06-07 | 2001-06-07 | Therapeutic agents - ii |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0111458A true BR0111458A (pt) | 2003-06-24 |
Family
ID=3822089
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0111423-9A BR0111423A (pt) | 2000-06-07 | 2001-06-07 | Métodos de tratamento ou profilaxia de condição inflamatória e de imunoproteção de um indivìduo, composição, computador e produto de programa de computador, processo de separação de diterpenos macrocìclicos de uma biomassa e uso de agente quìmico ou derivado ou análogo quìmico daquele |
BR0111458-1A BR0111458A (pt) | 2000-06-07 | 2001-06-07 | Métodos de tratamento ou profilaxia de condição inflamatória, de imunoproteção e de imunopotencialização de um indivìduo, composição, computador e produto de programa de computador |
BR0111375-5A BR0111375A (pt) | 2000-06-07 | 2001-06-07 | Métodos de tratamento ou profilaxia de uma condição ou distúrbio relacionada com pkc, de modulação da expressão de uma seq ência genética e de estimulação da ativação ou função de um promotor, computador e produto de programa de computador |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0111423-9A BR0111423A (pt) | 2000-06-07 | 2001-06-07 | Métodos de tratamento ou profilaxia de condição inflamatória e de imunoproteção de um indivìduo, composição, computador e produto de programa de computador, processo de separação de diterpenos macrocìclicos de uma biomassa e uso de agente quìmico ou derivado ou análogo quìmico daquele |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0111375-5A BR0111375A (pt) | 2000-06-07 | 2001-06-07 | Métodos de tratamento ou profilaxia de uma condição ou distúrbio relacionada com pkc, de modulação da expressão de uma seq ência genética e de estimulação da ativação ou função de um promotor, computador e produto de programa de computador |
Country Status (8)
Country | Link |
---|---|
US (6) | US20030195168A1 (pt) |
EP (3) | EP1296697A4 (pt) |
JP (3) | JP5822417B2 (pt) |
AU (1) | AUPQ801700A0 (pt) |
BR (3) | BR0111423A (pt) |
CA (3) | CA2411596C (pt) |
NZ (3) | NZ522425A (pt) |
WO (3) | WO2001093884A1 (pt) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPO864097A0 (en) | 1997-08-19 | 1997-09-11 | Peplin Pty Ltd | Anti-cancer compounds |
AUPQ801700A0 (en) | 2000-06-07 | 2000-06-29 | Peplin Research Pty Ltd | Enzyme and viral activation |
AUPQ923100A0 (en) | 2000-08-07 | 2000-08-31 | Peplin Research Pty Ltd | Treatment of prostate cancer |
EP2189473A3 (en) | 2000-10-27 | 2010-08-11 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic and proteins from streptococcus groups A & B |
US20050065205A1 (en) | 2002-03-07 | 2005-03-24 | Daniel Alkon | Methods for Alzheimer's disease treatment and cognitive enhance |
US6825229B2 (en) | 2002-03-07 | 2004-11-30 | Blanchette Rockefeller Neurosciences Institute | Methods for Alzheimer's Disease treatment and cognitive enhancement |
EP1597348A4 (en) * | 2002-08-26 | 2010-03-31 | Novartis Vaccines & Diagnostic | GENES OF STREPTOCOCCUS PRESERVED OR SPECIFIC |
US7220357B2 (en) * | 2003-07-24 | 2007-05-22 | Teva Gyógyszergyár Zártkörúen Múkó´dó´Résvénytársaság | Method of purifying macrolides |
CA2532369C (en) | 2003-07-31 | 2016-07-26 | Chiron Corporation | Immunogenic compositions for streptococcus pyogenes |
US8945589B2 (en) * | 2003-09-15 | 2015-02-03 | Novartis Vaccines And Diagnostics, Srl | Immunogenic compositions for Streptococcus agalactiae |
US20050070565A1 (en) * | 2003-09-26 | 2005-03-31 | Arnsten Amy F.T. | Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders |
TW200538181A (en) | 2004-05-18 | 2005-12-01 | Brni Neurosciences Inst | Treatment of depressive disorders |
US20060165716A1 (en) | 2004-07-29 | 2006-07-27 | Telford John L | Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
DE102004044428A1 (de) * | 2004-09-14 | 2006-03-30 | Toximed Gmbh | Verfahren und pharmazeutischer Wirkstoff zur Bekämpfung von Plasmodien |
CA2583803C (en) * | 2004-10-08 | 2014-11-25 | Giuliano Bensi | Immunogenic and therapeutic compositions for streptococcus pyogenes |
EP1807038A1 (en) * | 2004-11-03 | 2007-07-18 | Cognis France, S.A.S. | An extract of a plant belonging to the genus plukenetia volubilis and its cosmetic use |
US8106092B2 (en) * | 2004-12-13 | 2012-01-31 | Leo Laboratories Limited | Treatment of solid cancers |
US20090076132A1 (en) * | 2005-03-11 | 2009-03-19 | Gary Pekoe | Antiviral compositions and methods of treatment |
US20060204600A1 (en) * | 2005-03-11 | 2006-09-14 | Paul Konz | Dragon's blood anti-viral materials and methods |
WO2007016202A1 (en) | 2005-07-29 | 2007-02-08 | Blanchette Rockefeller Neurosciences Institute | Use of a pkc activator, alone or combined with a pkc inhibitor to enhance long term memory |
JP2009516651A (ja) * | 2005-11-14 | 2009-04-23 | ペプリン リサーチ プロプライエタリー リミティッド | 癌を治療するための他の薬剤と組み合わせたアンゲロイル置換インゲナンの使用 |
US20090215884A1 (en) * | 2005-11-25 | 2009-08-27 | Peplin Research Pty Ltd. | Method for wound healing |
GB0525680D0 (en) | 2005-12-16 | 2006-01-25 | Peplin Ltd | Therapeutic compositions |
PL2054431T3 (pl) * | 2006-06-09 | 2012-07-31 | Novartis Ag | Konformery adhezyn bakteryjnych |
EP2094297A2 (en) * | 2006-10-30 | 2009-09-02 | Novartis AG | Immunogenic and therapeutic compositions for streptococcus pyogenes |
CA2873179A1 (en) | 2007-02-09 | 2008-08-21 | Blanchette Rockefeller Neurosciences Institute | Use of bryostatins and neristatins in the treatment of cognitive impairment due to head trauma |
DK2152261T3 (en) * | 2007-04-30 | 2016-03-07 | Leo Lab Ltd | TREATMENT OF virus-induced INJURY |
US8287885B2 (en) | 2007-09-12 | 2012-10-16 | Novartis Ag | GAS57 mutant antigens and GAS57 antibodies |
KR100926408B1 (ko) | 2007-10-09 | 2009-11-12 | 고려대학교 산학협력단 | 감마허피스바이러스 재활성을 유도하는 감수 및 이를포함하는 약제학적 조성물 |
WO2009081274A2 (en) | 2007-12-21 | 2009-07-02 | Novartis Ag | Mutant forms of streptolysin o |
KR101089314B1 (ko) | 2010-06-07 | 2011-12-02 | 한국식품연구원 | 유포비아스테로이드를 유효성분으로 함유하는 비만 예방, 치료 또는 개선용 조성물 |
CN107011167A (zh) | 2010-07-20 | 2017-08-04 | 利奥实验室有限公司 | 制备巨大戟二萜醇‑3‑当归酸酯的方法 |
WO2012080466A2 (en) | 2010-12-17 | 2012-06-21 | Leo Pharma A/S | Ingenols for treating seborrheic keratosis |
NZ710133A (en) * | 2010-12-22 | 2016-08-26 | Leo Lab Ltd | Ingenol-3-acylates iii and ingenol-3-carbamates |
AU2011348638B2 (en) | 2010-12-22 | 2015-05-21 | Leo Laboratories Limited | 3-acyl-ingenols II |
BR112013015877A2 (pt) | 2010-12-22 | 2018-06-05 | Leo Laboratories Ltd | composto, uso de um composto, métodos de prevenção. tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica. |
CN102977019A (zh) * | 2011-09-06 | 2013-03-20 | 高峰 | 汉源乌头中一种新型c19二萜生物碱及其在制备抗肿瘤药物中的应用 |
JP2013063938A (ja) * | 2011-09-20 | 2013-04-11 | Kao Corp | メラニン産生促進剤 |
KR101406201B1 (ko) * | 2011-10-19 | 2014-06-12 | 한국생명공학연구원 | 인제난 타입의 디테르펜 화합물 및 이를 포함하는 바이러스 감염 질환의 치료 또는 예방용 약학적 조성물 |
WO2013088375A1 (en) | 2011-12-12 | 2013-06-20 | Leo Laboratories Limited | A topical composition comprising an ingenol derivative and an oily solvent |
EP2790672A1 (en) | 2011-12-12 | 2014-10-22 | Leo Laboratories Limited | Gel compositions |
US20140343141A1 (en) | 2011-12-12 | 2014-11-20 | Leo Laboratories Limited | Topical composition comprising an ingenol derivative and a surfactant-cosolvent mixture |
US20130251782A1 (en) | 2012-03-22 | 2013-09-26 | Leo Laboratories Limited | Topical application of ingenol mebutate with occlusion |
WO2013182688A1 (en) | 2012-06-08 | 2013-12-12 | Leo Laboratories Limited | A topical gel composition comprising an ingenol derivative and a solvent mixture |
US9624157B2 (en) | 2012-07-16 | 2017-04-18 | Leo Laboratories Limited | Process for the preparation of ingenol-3-angelate from 20-deoxy-ingenol |
CN103086882B (zh) * | 2013-02-05 | 2015-04-15 | 中国科学院新疆理化技术研究所 | 对叶大戟果实中的大环二萜类化合物及其制备方法和用途 |
US9526714B2 (en) | 2014-03-24 | 2016-12-27 | Leo Laboratories Limited | Method for treating skin lesions with ingenol mebutate |
EP3145903A4 (en) | 2014-05-23 | 2018-01-03 | Alphora Research Inc. | A continuous flow process for the preparation of ingenol-3-mebutate |
WO2016022358A1 (en) | 2014-08-08 | 2016-02-11 | The Regents Of The University Of California | Compositions and methods for reactivating latent viral infections |
CN104649901B (zh) * | 2015-02-09 | 2017-03-29 | 中国科学院昆明植物研究所 | 一种治疗光化性角化病的原料药物巨大戟醇甲基丁烯酸酯的制备方法 |
KR101735784B1 (ko) * | 2015-06-15 | 2017-05-15 | 대한민국(환경부 국립생물자원관장) | 트리고노스테몬 레이디오이데스 추출물을 이용한 항염증용 조성물 |
KR101735785B1 (ko) | 2015-06-15 | 2017-05-15 | 대한민국(환경부 국립생물자원관장) | 트리고노스테몬 레이디오이데스 추출물을 이용한 항알러지용 조성물 |
CN105348095A (zh) * | 2015-12-07 | 2016-02-24 | 西宁意格知识产权咨询服务有限公司 | 一种新的二萜类化合物及其制备方法和医药用途 |
US10275356B2 (en) * | 2015-12-11 | 2019-04-30 | Quanta Computer Inc. | Component carrier with converter board |
KR101755017B1 (ko) | 2016-08-10 | 2017-07-06 | 호서대학교 산학협력단 | 선녀배(Dudleya brittonii) 추출물의 제조방법 및 선녀배 추출물을 유효성분으로 함유하는 항암 또는 항산화용 조성물 |
JP7154539B2 (ja) * | 2016-08-18 | 2022-10-18 | 国立大学法人 奈良先端科学技術大学院大学 | 免疫調節剤 |
US10425485B2 (en) * | 2016-11-21 | 2019-09-24 | Cisco Technology, Inc. | Integrating information centric networking (ICN) over low power and lossy networks (LLNs) |
CN109912419A (zh) * | 2017-12-13 | 2019-06-21 | 复旦大学 | 巨大戟烷型二萜及其在制备抗艾滋病毒药物中的用途 |
KR101978915B1 (ko) * | 2018-08-08 | 2019-05-15 | 애경산업(주) | 포인세티아 추출물을 포함하는 여드름 예방 및 개선용 조성물 |
KR102508255B1 (ko) * | 2021-02-15 | 2023-03-09 | 연세대학교 산학협력단 | 비정형 pkc 활성화제를 함유하는 당 조절용 조성물 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3809749A (en) | 1971-03-05 | 1974-05-07 | Amazon Natural Drug Co | Topical pharmaceutical composition and method employing sap from the tree croton lechleri |
DE2902506A1 (de) | 1979-01-23 | 1980-07-24 | Deutsches Krebsforsch | Verwendung von nicht oder nur gering irritierenden und/oder promovierenden diterpenalkoholen und von derivaten davon als antineoplastische mittel |
US4418064A (en) * | 1982-09-29 | 1983-11-29 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids: treflorine, trenudine, and N-methyltrenudone |
US4560774A (en) * | 1982-11-17 | 1985-12-24 | Arizona State University | Macrocyclic lactones |
US5886019A (en) * | 1986-06-11 | 1999-03-23 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators. F. |
US5145842A (en) * | 1986-06-11 | 1992-09-08 | Alder Research Center Limited Partnership | Protein kinase c. modulators. d. |
IL82811A0 (en) | 1986-06-11 | 1987-12-20 | Alder Res Center Corp | Anti-inflammatory compositions containing methanol derivatives and novel compounds contained therein |
US5750568A (en) * | 1986-06-11 | 1998-05-12 | Procyon Pharmaceuticals, Inc. | Protein kinase C Modulators. L. |
US5643948A (en) * | 1986-06-11 | 1997-07-01 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators. K. |
US5891906A (en) * | 1986-06-11 | 1999-04-06 | Procyon Pharmaceuticals, Inc. | Polyacetate-derived phorboids having anti-inflammatory and other uses |
US5891870A (en) * | 1986-06-11 | 1999-04-06 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators Q |
US5886017A (en) * | 1986-06-11 | 1999-03-23 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators. E. |
US5962498A (en) | 1986-06-11 | 1999-10-05 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators. C. indolactam structural-types with anti-inflammatory activity |
US5716968A (en) | 1986-06-11 | 1998-02-10 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators. H. |
DE3805965A1 (de) | 1988-02-25 | 1989-09-07 | Tamas Geb Szenasi Eszter | Verwendung der pflanze euphorbia hirta l. und ihrer extrakte sowie ihrer wirkstoffe |
DE4102054A1 (de) | 1991-01-24 | 1992-07-30 | Geb Szenasi Tamas | Verwendung der pflanze euphorbia hirta l. und ihrer extrakte sowie ihrer wirkstoffe |
US5317009A (en) * | 1991-08-26 | 1994-05-31 | New York University | Anti-HIV proteins GAP 31, DAP 30 and DAP 32 and therapeutic uses thereof |
HU208790B (en) | 1991-12-05 | 1994-01-28 | Tamas | Process for producing pharmaceutical compositions against arc and aids, comprising euphorbia hirta l. plant or its parts or their extracts |
CN1047084C (zh) | 1993-03-30 | 1999-12-08 | 刘振宪 | 人参口服液及其制造方法 |
US6593371B1 (en) * | 1993-05-19 | 2003-07-15 | Jeff J. Staggs | Treatment for wart and related disorders |
CN1048164C (zh) | 1993-08-24 | 2000-01-12 | 吴雪姣 | 复方菝葜口服液 |
JP2913451B2 (ja) | 1994-06-22 | 1999-06-28 | 株式会社イナックス | 防水パンの高さ調整構造 |
JPH08245505A (ja) | 1994-09-09 | 1996-09-24 | Tosoh Corp | ジテルペン誘導体、その製造法及びそれを有効成分として含有する抗腫瘍剤 |
JPH08176004A (ja) | 1994-12-21 | 1996-07-09 | Lion Corp | 生体老化防止剤及び皮膚用組成物 |
JPH08176002A (ja) | 1994-12-27 | 1996-07-09 | Kao Corp | 細胞接着抑制剤 |
US5874464A (en) * | 1995-01-13 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Conformationally constrained diacylglycerol analogues |
CN1070372C (zh) | 1995-02-15 | 2001-09-05 | 赵国强 | 强力抗癌膏及其制造方法 |
WO1997015575A1 (en) | 1995-10-27 | 1997-05-01 | Procyon Pharmaceuticals, Inc. | Protein kinase c modulators. y. |
CN1058620C (zh) | 1995-11-12 | 2000-11-22 | 卢颖 | 一种治疗癌症的外用中成药及配备生产工艺 |
US5749111A (en) * | 1996-02-14 | 1998-05-12 | Teksource, Lc | Gelatinous cushions with buckling columns |
US5932613A (en) * | 1996-07-03 | 1999-08-03 | Millennium Pharmaceuticals, Inc. | Anticancer agents |
US6329459B1 (en) * | 1996-09-23 | 2001-12-11 | Bridgestone Corporation | Extended syndiotactic polystyrene-elastomeric block copolymers |
AUPO864097A0 (en) * | 1997-08-19 | 1997-09-11 | Peplin Pty Ltd | Anti-cancer compounds |
WO1999009884A1 (fr) * | 1997-08-26 | 1999-03-04 | Seiko Epson Corporation | Procede et appareil de mesure, de detection et de diagnostic d'un signal impulsionnel, de la fonction cardiaque et de l'intensite de mouvement |
US6228939B1 (en) * | 1999-05-19 | 2001-05-08 | Bridgestone Corporation | Thermoreversible gels comprising near gelation polymers |
EP1218420B1 (en) * | 1999-08-16 | 2005-01-26 | Dow Global Technologies Inc. | Hydrogenated block copolymers and optical media discs produced therefrom |
JP2001139468A (ja) * | 1999-11-11 | 2001-05-22 | Lead Chemical Co Ltd | 抗ウイルス作用を有するホルボール誘導体 |
AUPQ801700A0 (en) | 2000-06-07 | 2000-06-29 | Peplin Research Pty Ltd | Enzyme and viral activation |
AUPQ923100A0 (en) | 2000-08-07 | 2000-08-31 | Peplin Research Pty Ltd | Treatment of prostate cancer |
JP4880816B2 (ja) | 2000-12-15 | 2012-02-22 | 株式会社ヤクルト本社 | 皮膚老化防止剤 |
US6923993B2 (en) * | 2001-12-12 | 2005-08-02 | Nicholas J. Donato | Process of isolating extract from the Euphorbia obesa plant and methods for using the same |
JP3935360B2 (ja) | 2002-01-22 | 2007-06-20 | 丸善製薬株式会社 | ヒアルロン酸産生促進剤並びに皮膚化粧料及び美容用飲食品 |
EP1676132B1 (en) * | 2003-10-21 | 2014-01-22 | Cedars-Sinai Medical Center | Combination of chemotherapy and administration of glioma-antigen-pulsed dendritic cells in the treatment of glioma |
EA009669B1 (ru) | 2004-01-01 | 2008-02-28 | Панацея Биотек Лтд. | Фармацевтические композиции, содержащие экстракт euphorbia prostrata |
US8106092B2 (en) | 2004-12-13 | 2012-01-31 | Leo Laboratories Limited | Treatment of solid cancers |
US7378455B2 (en) * | 2005-06-30 | 2008-05-27 | General Electric Company | Molding composition and method, and molded article |
BRPI0504797B1 (pt) * | 2005-10-27 | 2020-02-04 | Pele Nova Biotecnologia S A | formulação tópica, método de tratamento cosmético para rejuvenescimento da pele, método de tratamento cosmético e uso de uma formulação |
JP2009516651A (ja) | 2005-11-14 | 2009-04-23 | ペプリン リサーチ プロプライエタリー リミティッド | 癌を治療するための他の薬剤と組み合わせたアンゲロイル置換インゲナンの使用 |
US20090215884A1 (en) | 2005-11-25 | 2009-08-27 | Peplin Research Pty Ltd. | Method for wound healing |
GB0525680D0 (en) | 2005-12-16 | 2006-01-25 | Peplin Ltd | Therapeutic compositions |
DK2152261T3 (en) | 2007-04-30 | 2016-03-07 | Leo Lab Ltd | TREATMENT OF virus-induced INJURY |
-
2000
- 2000-06-07 AU AUPQ8017A patent/AUPQ801700A0/en not_active Abandoned
-
2001
- 2001-06-07 CA CA2411596A patent/CA2411596C/en not_active Expired - Fee Related
- 2001-06-07 BR BR0111423-9A patent/BR0111423A/pt not_active IP Right Cessation
- 2001-06-07 JP JP2002501454A patent/JP5822417B2/ja not_active Expired - Fee Related
- 2001-06-07 WO PCT/AU2001/000679 patent/WO2001093884A1/en active IP Right Grant
- 2001-06-07 EP EP01937872A patent/EP1296697A4/en not_active Withdrawn
- 2001-06-07 JP JP2002501455A patent/JP5339662B2/ja not_active Expired - Fee Related
- 2001-06-07 CA CA2411726A patent/CA2411726C/en not_active Expired - Fee Related
- 2001-06-07 NZ NZ522425A patent/NZ522425A/en not_active IP Right Cessation
- 2001-06-07 BR BR0111458-1A patent/BR0111458A/pt not_active Application Discontinuation
- 2001-06-07 NZ NZ522427A patent/NZ522427A/en not_active IP Right Cessation
- 2001-06-07 JP JP2002501456A patent/JP5822418B2/ja not_active Expired - Fee Related
- 2001-06-07 BR BR0111375-5A patent/BR0111375A/pt not_active IP Right Cessation
- 2001-06-07 EP EP01937873.6A patent/EP1296698B1/en not_active Expired - Lifetime
- 2001-06-07 WO PCT/AU2001/000680 patent/WO2001093885A1/en active IP Right Grant
- 2001-06-07 WO PCT/AU2001/000678 patent/WO2001093883A1/en active IP Right Grant
- 2001-06-07 CA CA2411642A patent/CA2411642C/en not_active Expired - Fee Related
- 2001-06-07 NZ NZ522426A patent/NZ522426A/en not_active IP Right Cessation
- 2001-06-07 EP EP01940015.9A patent/EP1296699B1/en not_active Expired - Lifetime
-
2002
- 2002-12-09 US US10/315,319 patent/US20030195168A1/en not_active Abandoned
- 2002-12-09 US US10/315,288 patent/US7449492B2/en not_active Expired - Fee Related
- 2002-12-09 US US10/315,318 patent/US7838555B2/en not_active Expired - Fee Related
-
2004
- 2004-12-01 US US11/000,712 patent/US20050209192A1/en not_active Abandoned
-
2009
- 2009-08-18 US US12/543,087 patent/US20100048698A1/en not_active Abandoned
-
2011
- 2011-02-24 US US13/034,172 patent/US9314458B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0111458A (pt) | Métodos de tratamento ou profilaxia de condição inflamatória, de imunoproteção e de imunopotencialização de um indivìduo, composição, computador e produto de programa de computador | |
Mahajan et al. | A phytopharmacological overview on Ocimum species with special emphasis on Ocimum sanctum | |
EP1713490B1 (en) | Compositions for the treatment of atopic dermatitis, skin allergic conditions and acne | |
Okeniyi et al. | Phytochemical screening, cytotoxicity, antioxidant and antimicrobial activities of stem and leave extracts of Euphorbia heterophylla | |
Patil et al. | Hepatoprotective activity of Mentha arvensis Linn. leaves against CCl4 induced liver damage in rats | |
Varma et al. | The antiplaque efficacy of two herbal-based toothpastes: a clinical intervention | |
KR950000142A (ko) | 피부질환치료용 약제조성물 제조에 사용되는 히드록시산함유 l-카르니틴에스테르 및 아실 l-카르니틴에스테르의 용도 | |
Hussain et al. | Anti-inflammatory and antioxidant activities of Cordia dichotoma Forst | |
Yalcin et al. | Inhibition of catechol-O-methyltransferase (COMT) by some plant-derived alkaloids and phenolics | |
US20120316144A1 (en) | Antifungal agent | |
Germann et al. | Antioxidative properties of the gastrointestinal phytopharmaceutical remedy STW 5 (Iberogast®) | |
Adedoyin et al. | Cytotoxicity, antioxidant and antimicrobial activities of essential oil extracted from Euphorbia heterophylla plant | |
US11109607B2 (en) | Oil-based compositions for enhancing oral health and general wellness in humans | |
Bosly | Larvicidal potential of Thuja orientalis leaves and fruits extracts against Culex pipiens (Diptera: Culicidae) | |
Selles et al. | Chemical composition, antioxidant and in vitro antibacterial activities of essential oils of mentha spicata leaf from tiaret area (Algeria) | |
Oghenejoboh et al. | Chemical composition, cytotoxicity and antioxidant activities of essential oils of Parquetina nigrescens (Afz.) bullock from ibadan, Nigeria | |
LA BASY et al. | A Review: Activity Study of Itchy Leaves (Laportea decumana Roxb Wadd) as a Medicinal Plant. | |
Ramezani et al. | Effect of Geum kokanicum total extract on induced nociception and inflammation in male mice | |
Antia et al. | Wound healing, phytochemical and antimicrobial properties of Luffa cylindrica (Linn.) seed extracts | |
IT201800010241A1 (it) | Composizione contenente cannella per il trattamento coadiuvante di affezioni delle vie respiratorie e di malattie da raffreddamento in genere | |
Chebbac et al. | Research Article Chemical Analysis and Antioxidant and Antimicrobial Activity of Essential oils from Artemisia negrei L. against Drug-Resistant Microbes | |
NDUKWE et al. | Afzelia africana Seed Extract: Toxicity, Antidiarrhoeal and Chemical Assays. | |
Zulkurnain et al. | The Phytochemical and Pharmacological Effects of Hibiscus rosa-sinensis: A Review. | |
Andavarapu | Assessment of Antibacterial, Anti-Inflammatory and Antioxidant Activity of Allium Sativum (Garlic) Cloves Extracts–An in Vitro Study | |
MA51937B1 (fr) | Formulation médicale contre staphylococcus aureus résistant à la méticilline responsable des infections invasives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 31/455 (2006.01), A61K 31/22 (2006.01), A61K |